Polar Capital Biotech I GBP Hdg Inc
SpecialistPricing frequency
Daily
Dealing cut off time
14:45
Type
OEIC
Yield
–
NAV
£29.88
Income frequency
Annually
Ongoing charge
1.1%
Latest actual NAV date
13-11-2026
ISIN
IE00BFX4HX56
UCITS
Yes
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 30/09/2026 | % of assets |
|---|---|
| Amgen Inc | 5.18 |
| Alnylam Pharmaceuticals Inc | 4.64 |
| Madrigal Pharmaceuticals Inc | 4.62 |
| argenx SE | 4.45 |
| Arcutis Biotherapeutics Inc Ordinary Shares | 4.34 |
| Insmed Inc | 4.34 |
| Rhythm Pharmaceuticals Inc | 3.94 |
| Ascendis Pharma AS | 3.67 |
| Revolution Medicines Inc Ordinary Shares | 3.53 |
| Praxis Precision Medicines Inc Ordinary Shares | 3.19 |
Investment objective
The investment objective of the Fund is to achieve long term capital appreciation. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of biotechnology, diagnostics and life sciences tools companies.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.